These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9301984)

  • 21. Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.
    Fung-Tomc JC; Gradelski E; Kolek B; Minassian B; Pucci M; Kessler RE; Bonner DP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):386-93. PubMed ID: 7726503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000.
    Watanabe A; Tokue Y; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Yasui S; Murayama Y; Nukiwa T
    J Infect Chemother; 2001 Dec; 7(4):267-71. PubMed ID: 11810597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.
    Kitzis MD; Acar JF; Gutmann L
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():125-32. PubMed ID: 2808204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa.
    Thomson KS; Moland ES
    J Antimicrob Chemother; 2004 Aug; 54(2):557-62. PubMed ID: 15201229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004].
    Yamaguchi K; Murakami M; Takahashi A; Ishii Y; Iwata M; Itoh K; Oohara T; Watanabe N; Uehara N; Nomura F; Watanabe M; Yasujima M; Kasai T; Kanno H; Aihara M; Suwabe A; Yamahata K; Maesaki S; Hashikita G; Kaku M; Kanemitsu K; Miyake K; Oguri T; Yoshida H; Nishiyama K; Okada J; Tazawa Y; Komatsu M; Nakashima H; Takemura H; Kinoshita S; Okada M; Kobayashi S; Taminato T; Negayama K; Horii T; Murase M; Miyamoto H; Baba H; Kusano N; Mihara E; Ishigo S; Kambe M; Itaha H; Fujita N; Komori T; Ono J; Yoshimura H; Ichiyama S; Maeda S; Hirakata Y; Matsuda J; Yamanaka K; Mutara Y; Saikawa T; Hiramatsu K; Taminato S
    Jpn J Antibiot; 2005 Dec; 58(6):655-89. PubMed ID: 16521347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.
    Odenholt I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2365-70. PubMed ID: 9736564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ertapenem: a new carbapenem.
    Odenholt I
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1157-66. PubMed ID: 11772242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.
    Tsuji M; Ishii Y; Ohno A; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1998 Jan; 42(1):94-9. PubMed ID: 9449267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of enhanced antipseudomonal activity of BO-2727, a new injectable 1-beta-methyl carbapenem.
    Hazumi N; Fuse A; Matsuda K; Hashizume T; Sanada M
    Antimicrob Agents Chemother; 1995 Mar; 39(3):702-6. PubMed ID: 7793876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.
    Sumita Y; Fukasawa M
    J Antimicrob Chemother; 1995 Jul; 36(1):53-64. PubMed ID: 8537284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014).
    Rodloff AC; Dowzicky MJ
    Chemotherapy; 2017; 62(1):1-11. PubMed ID: 27216271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CP0569, a new broad-spectrum injectable carbapenem. Part 1: synthesis and structure-activity relationships.
    Aihara K; Kano Y; Shiokawa S; Sasaki T; Setsu F; Sambongi Y; Ishii M; Tohyama K; Ida T; Tamura A; Atsumi K; Iwamatsu K
    Bioorg Med Chem; 2003 Aug; 11(16):3475-85. PubMed ID: 12878141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.
    Malanoski GJ; Collins L; Wennersten C; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2009-16. PubMed ID: 8239623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic].
    Komoto A; Otsuki M; Nishino T
    Jpn J Antibiot; 1996 Apr; 49(4):352-66. PubMed ID: 8786626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imipenem: morphological changes and lethal effects on Pseudomonas aeruginosa.
    Carlone NA; Ferrero M; Cuffini AM; Cavallo R
    Drugs Exp Clin Res; 1987; 13(10):623-9. PubMed ID: 3123190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
    Kiratisin P; Keel RA; Nicolau DP
    Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.